GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (XCNQ:MRMD) » Definitions » Cyclically Adjusted Price-to-FCF

MariMed (XCNQ:MRMD) Cyclically Adjusted Price-to-FCF : (As of May. 20, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MariMed Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


MariMed Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for MariMed's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Cyclically Adjusted Price-to-FCF Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MariMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MariMed's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where MariMed's Cyclically Adjusted Price-to-FCF falls into.



MariMed Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

MariMed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, MariMed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.002/131.7762*131.7762
=-0.002

Current CPI (Mar. 2024) = 131.7762.

MariMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.003 100.560 -0.004
201409 0.000 100.428 0.000
201412 -0.012 99.070 -0.016
201503 -0.049 99.621 -0.065
201506 -0.058 100.684 -0.076
201509 -0.006 100.392 -0.008
201512 -0.023 99.792 -0.030
201603 -0.051 100.470 -0.067
201606 -0.005 101.688 -0.006
201609 -0.044 101.861 -0.057
201612 0.002 101.863 0.003
201703 -0.035 102.862 -0.045
201706 -0.042 103.349 -0.054
201709 -0.039 104.136 -0.049
201712 -0.077 104.011 -0.098
201803 -0.016 105.290 -0.020
201806 -0.023 106.317 -0.029
201809 -0.022 106.507 -0.027
201812 -0.020 105.998 -0.025
201903 -0.049 107.251 -0.060
201906 -0.104 108.070 -0.127
201909 -0.031 108.329 -0.038
201912 -0.021 108.420 -0.026
202003 -0.011 108.902 -0.013
202006 -0.004 108.767 -0.005
202009 -0.001 109.815 -0.001
202012 0.005 109.897 0.006
202103 0.014 111.754 0.017
202106 0.017 114.631 0.020
202109 0.013 115.734 0.015
202112 0.015 117.630 0.017
202203 0.014 121.301 0.015
202206 -0.034 125.017 -0.036
202209 0.004 125.227 0.004
202212 -0.002 125.222 -0.002
202303 -0.033 127.348 -0.034
202306 -0.016 128.729 -0.016
202309 0.007 129.860 0.007
202312 -0.008 129.419 -0.008
202403 -0.002 131.776 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MariMed  (XCNQ:MRMD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


MariMed Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of MariMed's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (XCNQ:MRMD) Business Description

Industry
Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R. Levine Senior Officer
Timothy Shaw Senior Officer